Clinical parameters | No. of patients | Aurora A mRNA expression | Aurora A amplification | Aurora A protein expression | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median(25%, 75%) | P | Negative(%) | Positive (%) | P | Negative(%) | Positive(%) | P | ||||||
Age(years) | |||||||||||||
<50 | 65 | 0.20 (0.08, 0.46) | 0.67* | 42 | (65) | 23 | (35) | 0.14‡ | 47 | (72) | 18 | (28) | 0.49‡ |
≥50 | 213 | 0.16 (0.07, 0.43) | 158 | (74) | 55 | (26) | 163 | (77) | 50 | (23) | |||
Menopause | |||||||||||||
Pre- | 73 | 0.18 (0.07, 0.42) | 0.89* | 50 | (68) | 23 | (32) | 0.45‡ | 54 | (74) | 19 | (26) | 0.72‡ |
Post- | 205 | 0.16 (0.08, 0.45) | 150 | (73) | 55 | (27) | 156 | (76) | 49 | (24) | |||
Tumor size (mm) | |||||||||||||
≤20 | 124 | 0.16 (0.08 , 0.36) | 0.25* | 97 | (78) | 27 | (22) | 0.035‡ | 99 | (80) | 25 | (20) | 0.13‡ |
>20 | 154 | 0.18 (0.08, 0.52) | 103 | (67) | 51 | (33) | 111 | (72) | 43 | (28) | |||
Nodal status | |||||||||||||
- | 165 | 0.16 (0.06, 0.38) | 0.14* | 125 | (76) | 40 | (24) | 0.089‡ | 134 | (81) | 31 | (19) | 0.0083‡ |
+ | 113 | 0.17 (0.09, 0.52) | 75 | (66) | 38 | (34) | 76 | (67) | 37 | (33) | |||
Nuclear grade | |||||||||||||
1 | 143 | 0.14 (0.06, 0.27) | 0.0004†| 114 | (80) | 29 | (20) | 0.0044‡ | 123 | (86) | 20 | (14) | <0.0001‡ |
2 | 66 | 0.22 (0.10, 0.57) | 38 | (58) | 28 | (42) | 45 | (68) | 21 | (32) | |||
3 | 68 | 0.31 (0.10, 0.76) | 48 | (71) | 20 | (29) | 41 | (60) | 27 | (40) | |||
ER | |||||||||||||
- | 61 | 0.20 (0.09, 0.66) | 0.14* | 43 | (70) | 18 | (30) | 0.78‡ | 38 | (62) | 23 | (38) | 0.0084‡ |
+ | 217 | 0.16 (0.08, 0.40) | 157 | (72) | 60 | (28) | 172 | (79) | 45 | (21) | |||
PgR | |||||||||||||
- | 94 | 0.23 (0.10, 0.56) | 0.016* | 71 | (76) | 23 | (24) | 0.34‡ | 67 | (71) | 27 | (29) | 0.24‡ |
+ | 184 | 0.14 (0.06, 0.38) | 129 | (70) | 55 | (30) | 143 | (78) | 41 | (22) | |||
HER2 | |||||||||||||
- | 236 | 0.16(0.08, 0.42) | 0.86* | 169 | (72) | 67 | (28) | 0.77‡ | 183 | (76) | 53 | (22) | 0.075‡ |
+ | 42 | 0.15(0.08, 0.48) | 31 | (74) | 11 | (26) | 27 | (64) | 15 | (36) | |||
Ki67 | |||||||||||||
≦15% | 91 | 0.11(0.06, 0.20) | <0.0001* | 74 | (81) | 17 | (18) | 0.013‡ | 79 | (87) | 12 | (13) | 0.0015‡ |
> 15% | 187 | 0.25(0.10, 0.58) | 126 | (67) | 61 | (32) | 131 | (70) | 56 | (30) | |||
Tumor Subtype | |||||||||||||
ER+/HER2- | 205 | 0.16(0.07, 0.39) | 0.084†| 150 | (73) | 55 | (27) | 0.39‡ | 162 | (79) | 43 | (21) | 0.082‡ |
ER+ or –/HER2+ | 42 | 0.15(0.08, 0.48) | 31 | (74) | 11 | (26) | 27 | (64) | 15 | (36) | |||
ER-/HER2- (Triple Negative) | 31 | 0.29(0.10, 0.79) | 19 | (61) | 12 | (39) | 21 | (68) | 10 | (32) |